

# Geoffrey L Uy

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6132474/geoffrey-l-uy-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

220  
papers

6,425  
citations

36  
h-index

77  
g-index

226  
ext. papers

7,956  
ext. citations

5  
avg, IF

5.31  
L-index

#	Paper	IF	Citations
220	Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.. <i>Science Translational Medicine</i> , <b>2022</b> , 14, eabm1375	17.5	2
219	Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2022</b> , 1-16	7.1	1
218	Adverse Outcomes in Acute Myeloid Leukemia Are Associated with Tumor Cell-Mediated Immunosuppression. <i>Blood</i> , <b>2021</b> , 138, 800-800	2.2	
217	Medical Simulation in High-Risk AML Improves Clinical Decision Making of Hematologists/Oncologists. <i>Blood</i> , <b>2021</b> , 138, 4985-4985	2.2	
216	Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	3
215	Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results. <i>Blood</i> , <b>2021</b> , 138, 2316-2316	2.2	
214	Social Deprivation Independently Predicts Survival in Younger Patients with Acute Myeloid Leukemia (Alliance). <i>Blood</i> , <b>2021</b> , 138, 1983-1983	2.2	
213	Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. <i>Blood</i> , <b>2021</b> ,	2.2	2
212	Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease. <i>Blood</i> , <b>2021</b> , 138, 3904-3904	2.2	
211	A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia. <i>Haematologica</i> , <b>2021</b> ,	6.6	3
210	Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. <i>Blood Advances</i> , <b>2021</b> , 5, 1474-1482	7.8	4
209	Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 924-935	59.2	42
208	Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. <i>Leukemia</i> , <b>2021</b> , 35, 3278-3281	10.7	5
207	Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , <b>2021</b> ,	6.6	1
206	CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Haematology</i> , <b>2021</b> , 8, e481-e491	14.6	19
205	BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. <i>Cancer</i> , <b>2021</b> , 127, 1246-1259	6.4	6
204	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. <i>Blood</i> , <b>2021</b> , 137, 751-762	6.2	77

203	Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. <i>International Journal of Hematology</i> , <b>2021</b> , 113, 92-99	2.3	7
202	A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 1441-1449	1.9	0
201	Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. <i>Blood Advances</i> , <b>2021</b> , 5, 1719-1728	7.8	8
200	Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 110	22.4	2
199	Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors. <i>Blood Advances</i> , <b>2021</b> ,	7.8	2
198	Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. <i>Blood Advances</i> , <b>2021</b> , 5, 4691-4700	7.8	1
197	Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. <i>Leukemia Research</i> , <b>2021</b> , 110, 106713	2.7	2
196	Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	2
195	CD123 bi-specific antibodies in development in AML: What do we know so far?. <i>Best Practice and Research in Clinical Haematology</i> , <b>2020</b> , 33, 101219	4.2	6
194	All I Really Need to Know I Learned From Pediatric Oncologists. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, 239-240.	3	3
193	The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced-intensity hematopoietic peripheral blood cell transplant - a retrospective study. <i>Transplant International</i> , <b>2020</b> , 33, 1089-1098	3	3
192	Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. <i>Haematologica</i> , <b>2020</b> , 105, e404-e407	6.6	6
191	Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1430-1441	4.3	3
190	Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, e464-e475	2.3	4
189	Combined Inhibition of CXCR4 Signaling and System xc- Transporter Activity Induces Synthetic Lethality in T-ALL Cells By Suppressing Gsh and Inducing Ferroptosis. <i>Blood</i> , <b>2020</b> , 136, 37-37	2.2	0
188	Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123/CD3 Bispecific DART Molecule, in Acute Myeloid Leukemia. <i>Blood</i> , <b>2020</b> , 136, 26-28	2.2	1
187	TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia. <i>Blood</i> , <b>2020</b> , 136, 3-4	2.2	2
186	Early Assessment of Treatment Response in Acute Myeloid Leukemia Using FLT PET/CT Imaging: A Trial of the ECOG-ACRIN Cancer Research Group (EAI141). <i>Blood</i> , <b>2020</b> , 136, 30-31	2.2	2

185	Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia. <i>Blood</i> , <b>2020</b> , 136, 16-18	2.2	7
184	Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab. <i>Blood</i> , <b>2020</b> , 136, 19-21	2.2	2
183	Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2020</b> , 136, 55-56	2.2	2
182	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML. <i>Blood</i> , <b>2020</b> , 136, 44-45	2.2	3
181	Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission. <i>Blood</i> , <b>2020</b> , 136, 46-48	2.2	2
180	Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 7510-7510	2.2	12
179	Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 7521-7521	2.2	0
178	Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy (IC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS7567-TPS7567	2.2	2
177	A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1156-1165	4.3	4
176	Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). <i>Journal of Geriatric Oncology</i> , <b>2020</b> , 11, 107-113	3.6	25
175	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , <b>2020</b> , 4, 3180-3190	7.8	4
174	Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. <i>Cancer Discovery</i> , <b>2020</b> , 10, 1854-1871	24.4	30
173	Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. <i>Blood</i> , <b>2020</b> , 135, 463-471	2.2	147
172	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. <i>Blood Advances</i> , <b>2020</b> , 4, 696-705	7.8	21
171	Clinical and functional significance of circular RNAs in cytogenetically normal AML. <i>Blood Advances</i> , <b>2020</b> , 4, 239-251	7.8	16
170	A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, e588-e593	2	2
169	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. <i>Leukemia</i> , <b>2019</b> , 33, 2599-2609	10.7	36
168	Choosing induction chemotherapy in therapy-related acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , <b>2019</b> , 32, 89-97	4.2	2

167	CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2287-2290	1.9	5
166	Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. <i>Leukemia</i> , <b>2019</b> , 33, 1620-1634	10.7	30
165	Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6524-6531	12.9	5
164	Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart <sup>®</sup> Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients. <i>Blood</i> , <b>2019</b> , 134, 733-733 <sup>2,2</sup>	2.2	11
163	Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degradator, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study. <i>Blood</i> , <b>2019</b> , 134, 232-232	2.2	7
162	Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML). <i>Blood</i> , <b>2019</b> , 134, 2547-2547	2.2	3
161	Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2019</b> , 134, 15-15	2.2	11
160	CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 2630-2630 <sup>2,2</sup>	2.2	2
159	Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart <sup>®</sup> Molecule for T-Cell Redirected Therapy. <i>Blood</i> , <b>2019</b> , 134, 5144-5144	2.2	3
158	Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy. <i>Blood</i> , <b>2019</b> , 134, 1366-1366	2.2	1
157	Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS. <i>Blood</i> , <b>2019</b> , 134, 3915-3915	2.2	4
156	Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 414-423	7.3	29
155	Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrnas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). <i>Blood</i> , <b>2019</b> , 134, 2694-2694	2.2	
154	A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia. <i>Blood</i> , <b>2019</b> , 134, 2650-2650	2.2	1
153	Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance). <i>Blood</i> , <b>2019</b> , 134, 1247-1247 <sup>2,2</sup>	2.2	
152	CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death. <i>Blood</i> , <b>2019</b> , 134, 2745-2745	2.2	0
151	Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). <i>Blood Advances</i> , <b>2019</b> , 3, 1714-1721	7.8	6
150	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , <b>2019</b> , 3, 670-680	7.8	35

149	Acute graft-versus-host disease following lung transplantation in a patient with a novel mutation. <i>Thorax</i> , <b>2018</b> , 73, 489-492	7.3	5
148	Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , <b>2018</b> , 132, 561-561	2.2	25
147	Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study. <i>Blood</i> , <b>2018</b> , 132, 1425-1425	2.2	6
146	The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML. <i>Blood</i> , <b>2018</b> , 132, 2706-2706	2.2	1
145	Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific DART Molecule for T-Cell Redirected Therapy. <i>Blood</i> , <b>2018</b> , 132, 2738-2738	2.2	7
144	A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701. <i>Blood</i> , <b>2018</b> , 132, 309-309	2.2	10
143	Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 7000-7000	2.2	3
142	CX-01, an inhibitor of CXCL12/CXCR4 axis and of platelet factor 4 (PF4), with azacitidine (AZA) in patients with hypomethylating agent (HMA) refractory AML and MDS.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 7027-7027	2.2	3
141	Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. <i>Oncotarget</i> , <b>2018</b> , 9, 4354-4365	3.3	11
140	Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 7040-7040	2.2	
139	Phase 1 trial of pegzilarginase in patients (pts) with relapsed/refractory (R/R) AML or MDS refractory to hypomethylating agents (HMAs).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 7031-7031	2.2	1
138	Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). <i>Blood</i> , <b>2018</b> , 132, 89-89	2.2	2
137	Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614). <i>Blood</i> , <b>2018</b> , 132, 1386-1386	2.2	
136	Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study. <i>Blood</i> , <b>2018</b> , 132, 2170-2170	2.2	
135	Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance. <i>Blood</i> , <b>2018</b> , 132, 5277-5277	2.2	
134	The CXCR4 Antagonist, BL8040, Is Highly Active Against Human T-ALL in Preclinical Models. <i>Blood</i> , <b>2018</b> , 132, 2700-2700	2.2	1
133	Prognostic and Biologic Significance of Long Non-Coding RNA (lncRNA) Profiling in Cytogenetically Abnormal Acute Myeloid Leukemia (CA-AML). <i>Blood</i> , <b>2018</b> , 132, 2767-2767	2.2	
132	Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product. <i>Blood</i> , <b>2018</b> , 132, 118-118	2.2	



131	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 726-733	4.7	45
130	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2684-2692	2.2	446
129	A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel - fusion. <i>Blood Advances</i> , <b>2018</b> , 2, 1295-1299	7.8	18
128	Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , <b>2018</b> , 13, 417-425	4.4	47
127	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1028-1041	59.2	64
126	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1425-1433	8.7	35
125	Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 2386-2398	59.2	708
124	Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E49-E52	7.1	9
123	T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 648-653	4.7	28
122	A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia. <i>Blood Cancer Journal</i> , <b>2017</b> , 7, e542	7	35
121	Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 769-771	4.4	3
120	Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. <i>Blood</i> , <b>2017</b> , 129, 1397-1401	2.2	17
119	Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1282-1289	4.7	4
118	Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , <b>2017</b> , 102, 1391-1400	6.6	23
117	Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. <i>Blood</i> , <b>2017</b> , 129, 2680-2692	2.2	48
116	Fresh or Cryopreserved CD34-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1072-1077	4.7	20
115	NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2017</b> , 15, 1091-1102	7.3	44
114	Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. <i>Cancer Medicine</i> , <b>2017</b> , 6, 2814-2821	4.8	11

113	Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 2065-2069	4.7	16
112	Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. <i>Transplant Infectious Disease</i> , <b>2017</b> , 19, e12629	2.7	55
111	Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. <i>Leukemia</i> , <b>2017</b> , 31, 872-881	10.7	64
110	A phase 2 study incorporating sorafenib into the chemotherapy for older adults with -mutated acute myeloid leukemia: CALGB 11001. <i>Blood Advances</i> , <b>2017</b> , 1, 331-340	7.8	42
109	Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , <b>2017</b> , 130, 637-637	2.2	41
108	Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , <b>2017</b> , 130, 725-725	2.2	12
107	Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML. <i>Blood</i> , <b>2017</b> , 130, 816-816	2.2	6
106	US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. <i>Blood Advances</i> , <b>2016</b> , 1, 250-259	7.8	91
105	TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2023-2036	59.2	493
104	Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. <i>Blood</i> , <b>2016</b> , 127, 122-31	2.2	120
103	Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1851-1860	4.7	91
102	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 248-257	4.7	27
101	A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 728-30	1.9	9
100	Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1. <i>Blood</i> , <b>2016</b> , 128, 1070-1070	2.2	25
99	The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia. <i>Blood</i> , <b>2016</b> , 128, 2745-2745	2.2	3
98	A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Hematopoietic Cell Transplantation for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: CALGB Study 10701 (Alliance). <i>Blood</i> , <b>2016</b> , 128, 2782-2782	2.2	5
97	Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7000-7000	2.2	116
96	Haploidentical Transplant with Peripheral Blood Hematopoietic Cell Grafts in Older Adults with AML or MDS. <i>Blood</i> , <b>2016</b> , 128, 4658-4658	2.2	



95	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , <b>2016</b> , 122, 3005-3014	6.4	32
94	Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. <i>Haematologica</i> , <b>2016</b> , 101, e465-e468	6.6	32
93	Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1324-1329	4.7	22
92	A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 2535-40	1.9	9
91	Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. <i>Leukemia Research</i> , <b>2016</b> , 49, 1-6	2.7	26
90	Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 1425-30	4.7	9
89	Targeting the microenvironment in acute myeloid leukemia. <i>Current Hematologic Malignancy Reports</i> , <b>2015</b> , 10, 126-31	4.4	52
88	Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 1513-8	4.4	30
87	Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. <i>Leukemia Research</i> , <b>2015</b> , 39, 1437-42	2.7	10
86	Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 1761-9	4.7	103
85	Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. <i>Blood</i> , <b>2015</b> , 126, 2484-90	2.2	150
84	Acute Lymphoblastic Leukemia, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 1240-79	7.3	58
83	Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 1057-62	4.4	17
82	A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome. <i>Blood</i> , <b>2015</b> , 126, 1686-1686	2.2	1
81	Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes. <i>Blood</i> , <b>2015</b> , 126, 1950-1950	2.2	4
80	The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia. <i>Blood</i> , <b>2015</b> , 126, 2546-2546	2.2	12
79	Development of Xpert <sup>®</sup> BCR-ABL Ultra, an Automated and Standardized Multiplex Assay with Required Performance Characteristics for BCR-ABL1 Quantitative Measurement on an International Reporting Scale. <i>Blood</i> , <b>2015</b> , 126, 2793-2793	2.2	5
78	CD34+ Selected Infusions of Fresh or Cryopreserved Peripheral Blood Stem Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , <b>2015</b> , 126, 3098-3098 <sup>1</sup>	2.2	1

77	Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001). <i>Blood</i> , <b>2015</b> , 126, 319-319	2.2	9
76	Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy. <i>Blood</i> , <b>2015</b> , 126, 610-610	2.2	1
75	Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. <i>Blood</i> , <b>2015</b> , 126, 689-689	2.2	1
74	Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60. <i>Blood</i> , <b>2015</b> , 126, 796-796	2.2	8
73	CXCR4/CXCL12 as a Therapeutic Target <b>2015</b> , 607-615		
72	Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , <b>2015</b> , 126, 3144-3144	2.2	2
71	Clinical Evaluation of Xpert <sup>®</sup> BCR-ABL Ultra, an Automated and Standardized Cartridge-Based Assay for the Quantification of BCR-ABL1. <i>Blood</i> , <b>2015</b> , 126, 5170-5170	2.2	
70	T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy. <i>Blood</i> , <b>2015</b> , 126, 3106-3106	2.2	
69	Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. <i>International Journal of Hematology</i> , <b>2014</b> , 99, 272-8	2.3	28
68	Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 46-52	4.7	72
67	Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 487-92	7.1	8
66	A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. <i>American Journal of Hematology</i> , <b>2014</b> , 89, E103-8	7.1	13
65	Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 1124-6	4.4	22
64	Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 202-8	4.7	27
63	A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 1366-70	4.4	6
62	Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation. <i>Blood</i> , <b>2014</b> , 124, 2447-2447	2.2	1
61	Acute Myeloid Leukemia Patients with Pre-Transplant Ablated Marrows Have Similar Rates of Survival and Relapse Compared to Patients in Complete Remission after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , <b>2014</b> , 124, 2557-2557	2.2	1
60	Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance). <i>Blood</i> , <b>2014</b> , 124, 8-8	2.2	27

59	A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS. <i>Blood</i> , <b>2014</b> , 124, 1931-1931	2.2	
58	Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. <i>Blood</i> , <b>2014</b> , 124, 2456-2456 <sup>1</sup>	2.2	
57	G-CSF Augments Inotuzamab-Mediated Clearance of Acute Lymphoblastic Leukemia from the Bone Marrow. <i>Blood</i> , <b>2014</b> , 124, 5502-5502	2.2	
56	Impact of Remission Status on Outcomes in AML Patients ≥60 Years of Age after Allogeneic Stem Cell Transplantation. <i>Blood</i> , <b>2014</b> , 124, 1263-1263	2.2	
55	Chemotherapy Versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplant: A Retrospective Review. <i>Blood</i> , <b>2014</b> , 124, 3944-3944	2.2	
54	Preclinical and Clinical Pharmacodynamics of Pan-Pim Inhibition By AZD1208 in Acute Myeloid Leukemia: Assessment of Pim Isoform Dependency for Bad and 4EBP1 Phosphorylation. <i>Blood</i> , <b>2014</b> , 124, 906-906	2.2	1
53	A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2014</b> , 124, 5292-5292	2.2	
52	Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. <i>Blood</i> , <b>2014</b> , 124, 850-850 <sup>2,2</sup>	2.2	
51	A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML. <i>Leukemia</i> , <b>2013</b> , 27, 725-8	10.7	37
50	Dual receptor T cells mediate pathologic alloreactivity in patients with acute graft-versus-host disease. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 188ra74	17.5	27
49	Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001). <i>Blood</i> , <b>2013</b> , 122, 2653-2653	2.2	2
48	Targeting CD123 In Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecules (DARTs <sup>2</sup> ). <i>Blood</i> , <b>2013</b> , 122, 360-360	2.2	13
47	A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 5492-5492	2.2	3
46	A Phase I Dose Escalation Study Of Oral Bexarotene In Combination With Intravenous Decitabine In Patients With AML. <i>Blood</i> , <b>2013</b> , 122, 3931-3931	2.2	
45	Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial. <i>Blood</i> , <b>2013</b> , 122, 2816-2816	2.2	
44	Targeting Bone Marrow Lymphoid Niches In Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2013</b> , 122, 1398-1398 <sup>2</sup>	2.2	
43	Predicting Autologous Stem Cell Mobilization Failure In Hematologic Malignancies. <i>Blood</i> , <b>2013</b> , 122, 2034-2034	2.2	1
42	Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. <i>Transplant Infectious Disease</i> , <b>2012</b> , 14, 259-67	2.7	19

41	A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. <i>Blood</i> , <b>2012</b> , 119, 3917-24	2.2	292
40	Expression and function of PML-RARA in the hematopoietic progenitor cells of Ctsg-PML-RARA mice. <i>PLoS ONE</i> , <b>2012</b> , 7, e46529	3.7	14
39	Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e278-82	2.2	7
38	Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2011</b> , 17, 1646-52	4.7	76
37	A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. <i>Blood</i> , <b>2011</b> , 117, 1828-33	2.2	95
36	Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 1445-55	15.9	82
35	Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia- Preliminary Results From a Phase I Study. <i>Blood</i> , <b>2011</b> , 118, 82-82	2.2	11
34	Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older with Acute Myeloid Leukemia,. <i>Blood</i> , <b>2011</b> , 118, 3633-3633	2.2	
33	A Phase 1 Study of Concomitant High Dose Lenalidomide and 5-Azacytidine Induction in the Treatment of Acute Myeloid Leukemia,. <i>Blood</i> , <b>2011</b> , 118, 3616-3616	2.2	
32	Phase I Study of Cladribine (2-chlorodeoxyadenosine), Cytarabine and G-CSF Based Induction Therapy (CLAG) with ATRA (All-trans retinoic acid) and Midostaurin for Relapsed/Refractory AML,. <i>Blood</i> , <b>2011</b> , 118, 3609-3609	2.2	
31	Limited engraftment of low-risk myelodysplastic syndrome cells in NOD/SCID gamma-C chain knockout mice. <i>Leukemia</i> , <b>2010</b> , 24, 1662-4	10.7	20
30	A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemia. <i>Blood</i> , <b>2010</b> , 116, 3604-10	2.2	11
29	Phase I Study of Panobinostat Plus Decitabine In Elderly Patients with Advanced MDS or AML.. <i>Blood</i> , <b>2010</b> , 116, 1060-1060	2.2	2
28	Decitabine for Older AML Patients: An Effective Therapy Associated with Short Hospitalization and No Invasive Fungal Infection.. <i>Blood</i> , <b>2010</b> , 116, 1063-1063	2.2	0
27	Phase I Study of Intravenous Plerixafor Added to a Mobilization Regimen of G-CSF In Lymphoma Patients Undergoing Autologous Stem Cell Collection. <i>Blood</i> , <b>2010</b> , 116, 823-823	2.2	1
26	A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. <i>American Journal of Hematology</i> , <b>2009</b> , 84, 560-4	7.1	36
25	Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. <i>American Journal of Hematology</i> , <b>2009</b> , 84, 733-7	7.1	38
24	Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors. <i>Oncology Reviews</i> , <b>2009</b> , 3, 59-70	4.3	

23	Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study. <i>Bone Marrow Transplantation</i> , <b>2009</b> , 43, 793-800	4.4	23
22	Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. <i>Bone Marrow Transplantation</i> , <b>2009</b> , 44, 13-7	4.4	17
21	BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. <i>Blood</i> , <b>2009</b> , 114, 1340-3	2.2	138
20	Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 14-23	1.9	10
19	Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. <i>Blood</i> , <b>2009</b> , 113, 6206-14	2.2	405
18	Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.. <i>Blood</i> , <b>2009</b> , 114, 3417-3417 <sup>1</sup>	2.2	1
17	A Phase I/II Study of Chemosensitization with the CXCR4 Antagonist Plerixafor in Relapsed or Refractory AML.. <i>Blood</i> , <b>2009</b> , 114, 787-787	2.2	4
16	A Phase II Study of High Dose Lenalidomide as Initial Therapy for Acute Myeloid Leukemia in Patients > 60 Years Old.. <i>Blood</i> , <b>2009</b> , 114, 842-842	2.2	4
15	Busulfan/Fludarabine/Thymoglobulin as a Reduced Intensity Conditioning Regimen for Lymphoid Malignancies.. <i>Blood</i> , <b>2009</b> , 114, 3335-3335	2.2	
14	Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2008</b> , 14, 1045-1056	4.7	267
13	Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. <i>Expert Opinion on Biological Therapy</i> , <b>2008</b> , 8, 1797-804	5.4	77
12	Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease.. <i>Blood</i> , <b>2008</b> , 112, 1944-1944	2.2	8
11	A Single-Institution Randomized Prospective Trial of Pre-Emptive Therapy with Oral Valganciclovir Compared with IV Ganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplant (aHSCT), Delayed until Viral Load (VL) >10,000 Copies/ml or >5,000 Copies/ml X 2. <i>Blood</i> , <b>2008</b> , 112, 4340-4340	2.2	
10	A Protease-Resistant PML-RAR $\alpha$ Has Increased Leukemogenic Potential in a Murine Model of Acute Promyelocytic Leukemia (APL).. <i>Blood</i> , <b>2008</b> , 112, 930-930	2.2	
9	Allogeneic Stem Cell Transplantation Conditioning for MDS and AML with Clofarabine, Cytarabine and ATG. <i>Blood</i> , <b>2008</b> , 112, 4427-4427	2.2	
8	Bortezomib inhibits osteoclast activity in patients with multiple myeloma. <i>Clinical Lymphoma and Myeloma</i> , <b>2007</b> , 7, 587-9		30
7	FLAG-IM (Fludarabine, Ara-C, G-CSF, Idarubicin, Mylotarg) Is an Effective Salvage Regimen Producing High Rates of Remission (CR+CRi) in Relapsed/Refractory AML.. <i>Blood</i> , <b>2007</b> , 110, 1855-1855	2.2	1
6	Kinetics of Human and Murine Mobilization of Acute Myeloid Leukemia in Response to AMD3100.. <i>Blood</i> , <b>2007</b> , 110, 867-867	2.2	3



5	Phase II Study of High Dose Lenalidomide as Initial Treatment for Older Acute Myeloid Leukemia Patients: Early Results Show a Significant Reduction of Bone Marrow Blasts after 14 Days of Therapy.. <i>Blood</i> , <b>2007</b> , 110, 916-916	2.2	6
4	A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.. <i>Blood</i> , <b>2007</b> , 110, 1451-1451	2.2	
3	Kinetics of Stem Cell and Lymphoid Subset Mobilization in Response to Intravenous (IV) AMD3100 in Mouse and Man.. <i>Blood</i> , <b>2007</b> , 110, 1203-1203	2.2	
2	Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. <i>Oncogene</i> , <b>2001</b> , 20, 1839-51	9.2	173
1	Exhaled nitric oxide correlates with experimental lung transplant rejection. <i>Annals of Thoracic Surgery</i> , <b>2000</b> , 69, 210-5	2.7	12